Fig. 3: Origin of AgPd0.38’s observed selectivity.
From: Surface-bound reactive oxygen species generating nanozymes for selective antibacterial action
a Synchrotron soft X-ray microscopy images of silver nanocube (AgNC) in aqueous dispersions of S. aureus and E. coli. b Scanning electron microscopy (SEM) images of bacteria treated with AgPd0.38, AgPd0.08, and PBS. c Cellular uptake of AgPd0.38 by Raw 264.7 cells at 4 and 37 °C. Cellular uptake here is defined as the relative mass ratio of AgPd0.38 associated onto and internalized into cells to the total AgPd0.38 added. d Schematic illustration on endocytosis pathways and their respective inhibitors. e Cellular uptake of AgPd0.38 by Raw 264.7 cells in the presence of an inhibitor at 37 °C. Control denotes Raw 264.7 cells treated similarly but in the absence of any inhibitor. f Viability ratios of Raw 264.7 cells treated with AgPd0.38 (100 μg/mL) in the presence of dynasore. Control denotes Raw 264.7 cells treated similarly but in the absence of dynasore. g Schematic illustration on the preparation of AgPd0.38@P and the specific recognition between P-selectin naturally present on platelet membrane and CD44 receptors over-expressed on 4T1 cells. h Cellular uptake of AgPd0.38@P and AgPd0.38 by 4T1 cells. i Viability ratios of 4T1 cells after treatment with AgPd0.38@P and AgPd0.38. j Cellular uptake of AgPd0.38 by adherent versus suspended Ana-1 cells. k Viability ratios of adherent versus suspended Ana-1 cells after treatment with AgPd0.38. l MBC99.9 values of AgPd0.38@lipid versus AgPd0.38. m Survival ratios of S. aureus cells after 10-min treatment with a photodynamic nanoparticle (Ce6/PLGA@lipid, or Ce6/PLGA) and then 5-min irradiation with a solar simulator (at 0.1 W/m2). n Viability ratios of Raw 264.7 cells after 4-h treatment with a photodynamic nanoparticle (Ce6/PLGA@lipid, or Ce6/PLGA) and then 5-min irradiation with a solar simulator (at 0.1 W/m2). Each in vitro antibacterial or cell viability assay was carried out in triplicate and the reported results are averages of two independent trials. Plots on source date are provided as Supplementary Figures. Source data are provided in the Source Data file.
